Cardiorespiratory fitness and inflammation among sedentary people with HIV; helping patients increase physical activity; transwomen and metabolic syndrome; failed treatment of precancerous cervical lesions.
Do the guidelines for laboratory monitoring still make sense when our HIV treatments have become so safe and effective? Paul E. Sax, M.D., offers a revised -- and deliberately provocative -- recommendation.
Unmet subsistence needs and clinical outcomes; finding HIV treatment success alongside quality-of-life issues; the potential value of facility-level HIV care continuum data; stimulant use and viral suppression.
Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?
A cellphone attachment that detects HIV RNA; HIV-2 does indeed often progress to AIDS; CD4 count declines and incident hepatitis C coinfection; the global demographics of non-Hodgkin lymphoma.
The case for a new measurement of HIV treatment success; PrEP and HIV incidence in Australia; benefits of moderate exercise among older people with HIV; CD4 recovery rates after long-term viral suppression.
Post-incarceration HIV outcomes worse among women; no drug resistance despite apparent PrEP failure; cost-efficacy of adherence self-management; additional cancers in HIV-positive cancer survivors.
How food insecurity feeds inflammation; racial disparities in HPV16 prevalence; how HIV meds affect pre-existing neurocognitive impairment; central nervous system inflammation in the setting of HIV treatment success.
Among this week's selection of four studies, we learn about data from a large study exploring the relative durability of first-line antiretroviral regimens stratified by drug class. (Spoiler alert: Older protease inhibitors don't do so well.)
Sobering data regarding linkage to HIV care among women in the U.S.; Latinx HIV incidence inequalities; efficacy of hepatitis C treatment among people with HIV; and a call for frequent STI testing among at-risk people with HIV.